These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32256445)

  • 1. Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats.
    Lv Q; Le L; Xiang J; Jiang B; Chen S; Xiao P
    Front Endocrinol (Lausanne); 2020; 11():111. PubMed ID: 32256445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
    Tan F; Long X; Du J; Yuan X
    Biomed Pharmacother; 2023 Oct; 166():115289. PubMed ID: 37572641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
    Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
    PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
    Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.
    Vercalsteren E; Karampatsi D; Buizza C; Nyström T; Klein T; Paul G; Patrone C; Darsalia V
    Cardiovasc Diabetol; 2024 Feb; 23(1):88. PubMed ID: 38424560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
    Park JH; Seo I; Shim HM; Cho H
    J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
    Luippold G; Klein T; Mark M; Grempler R
    Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
    Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE
    Han JH; Oh TJ; Lee G; Maeng HJ; Lee DH; Kim KM; Choi SH; Jang HC; Lee HS; Park KS; Kim YB; Lim S
    Diabetologia; 2017 Feb; 60(2):364-376. PubMed ID: 27866224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.
    Hierro-Bujalance C; Infante-Garcia C; Del Marco A; Herrera M; Carranza-Naval MJ; Suarez J; Alves-Martinez P; Lubian-Lopez S; Garcia-Alloza M
    Alzheimers Res Ther; 2020 Apr; 12(1):40. PubMed ID: 32264944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
    Yang Q; Deng L; Feng C; Wen J
    PeerJ; 2024; 12():e17055. PubMed ID: 38500527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
    Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM
    Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
    Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
    Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary Supplementation of Vine Tea Ameliorates Glucose and Lipid Metabolic Disorder via Akt Signaling Pathway in Diabetic Rats.
    Xiang J; Lv Q; Yi F; Song Y; Le L; Jiang B; Xu L; Xiao P
    Molecules; 2019 May; 24(10):. PubMed ID: 31096578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.
    Hammoudi N; Jeong D; Singh R; Farhat A; Komajda M; Mayoux E; Hajjar R; Lebeche D
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):233-246. PubMed ID: 28643218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
    PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.